Introduction
Various substituted thiazolo[3,2-a]benzimidazole derivatives are associated with diverse pharmacological activities (Fukunaga et al., 2007; Kohara et al., 2005) . For example, 3-(4-chlorophenyl)thiazolo[3,2-a]benzimidazole-2-acetic acid or tilomisole 251) was used in the treatment of cancer (Dillman et al., 1992) and rheumatoid arthritis besides its benefi ts as both anti-infl ammatory drug (Eickhoff et al., 1996) and immunomodulatory agent (Gilman et al., 1987) . In addition, several 1,3-thiazole (Anandan et al., 2007) , 1,4-benzothiazine (Schiaffella et al., 2006) , quinoxaline (Rong et al., 2007) , and imidazo[1,2-a]pyridine (Ismaila et al., 2008) derivatives are of signifi cant pharmaceutical importance.
Prompted by these observations and as a continuation of our previous work on the chemistry and biological properties of thiazolo[3,2-a]benzimidazole derivatives (Abdel-Aziz et al., 2008; Hamdy et al., 2007) and the synthesis of biologically active heterocycles (Dawood et al., 2005 (Dawood et al., , 2007 , we present in this study a novel approach to the synthesis of a battery of compounds starting from the key precursor 2-bromo-1-(6-bromo-3-methylthiazolo[3,2-a]benzimidazol-2-yl) ethanone (5). These compounds were further screened for their immunomodulatory, anticancer, anti-infl ammatory, and antioxidant activities.
Experimental

Chemistry
Melting points were measured with a Gallenkamp apparatus and are uncorrected. IR spectra were recorded on a Shimadzu FT-IR 8101 PC infrared spectrophotometer. The NMR spectra were recorded on a Varian Mercury VX-300 NMR spectrometer.
1 H NMR spectra were run at 300 MHz in deuterated dimethylsulfoxide ). Chemical shifts are quoted in d and were related to those of the solvents. Mass spectra were measured on a GCMS-QP1000 EX spectrometer at 70 eV. Elemental analyses were 1-(6-Bromo-3-methyl-1,3-thiazolo[3,2-a]benzimidazol-2-yl)ethanone (2) was prepared by bromination at ambient temperature of 1-(3-methylthiazolo[3,2-a]benzimidazol-2-yl)ethanone (1). The structure of 2 was determined by single-crystal X-ray diffraction. The precursor 5 was synthesized by heating a mixture of acetyl 2 and bromine. Various 2-substituted 6-bromo-3-methylthiazolo[3,2-a]benzimidazoles containing 1,3-thiazole, 1,4-benzothiazine, quinoxaline or imidazo[1,2-a]pyridine moieties were prepared starting from bromoacetyl 5. Taken together from the biological investigations, 2, 5, and 7a were potent immunosuppressors against both macrophages and T-lymphocytes, and 7b, 11b, and 14 were potent immunostimulators towards both types of immune cells. The results also revealed that, among others, 2 and 14 were the most signifi cant inhibitors of LPS-stimulated NO generation, and that 5, 7a, and 7b had a weak radical scavenging activity against DPPH radicals. Moreover, 2, 5, and 7a had a concomitant strong cytotoxicity against colon carcinoma, hepatocellular carcinoma, and lymphoblastic leukemia cells. Collectively, compounds 2, 5, and 7a are multipotent compounds with promising biological activities.
Synthesis of New 2-Substituted 6-Bromo-3-methylthiazolo[3,2-a]-benzimidazole Derivatives and their Biological Activities
carried out at the Microanalytical Center of Cairo University. 
1-
benzimidazol-2-yl)ethanone (2)
A solution of 1-(3-methylthiazolo[3,2-a]benzimidazol-2-yl)ethanone (1) (2.3 g, 10 mmol) in glacial acetic acid (50 ml) was stirred at ambient temperature, while a bromine solution (1.6 g, 10 mmol) in glacial acetic acid (15 ml) was added drop-wise over a period of 30 min. After the addition was completed, the mixture was stirred at room temperature for further 30 min. 
X-ray crystallography of 2
A single crystal of 2 was obtained by slow evaporation from a mixture of toluene and petroleum ether (40 -60). The crystal structure was solved and refi ned using maXus (Bruker Nonius, Delft, The Netherlands and MacScience, Yokohama, Japan) (Altomare et al., 1994) . Mo-Kα radiation (λ = 0.71073 Å) and a graphite monochromator were used for data collection.
Crystal data of 2: empirical formula, C 12 H 9 BrN 2 OS; M r , 309.190; crystal system, monoclinic; space group, C2/c; unit cell dimensions, a = 11.4230(6) Å, b = 8.8509 (5) 
2-
ethanone (5)
Method A A solution of 1-(3-methylthiazolo[3,2-a]benzimidazol-2-yl)ethanone (1) (2.3 g, 10 mmol) in glacial acetic acid (50 ml) was refl uxed while stirring. To the hot solution, a bromine solution (3.2 g, 20 mmol) in glacial acetic acid (25 ml) was added drop-wise over a period of 30 min with stirring; the mixture was maintained at 90 -100 °C. After the addition was completed the mixture was stirred vigorously at room temperature for further 1.5 h, till evolution of hydrogen bromide gas ceased and precipitation of the product was completed. 
Method B
This reaction was carried out by the same procedure as described in method A using equimolar quantities of both 1-(6-bromo-3-methyl-1,3-thiazolo[3,2-a]benzimidazol-2-yl)ethanone (2) and bromine. 
2-(2-
benzimidazole (7a)
To a solution of the bromoacetyl derivative 5 (0.39 g, 1 mmol) in absolute ethanol (20 ml), thiourea (6a) (0.076 g, 1 mmol) was added. The mixture was refl uxed for 5 h, then left to cool. The reaction mixture was treated with a solution of sodium acetate trihydrate till complete precipitation of the product. The solid that formed was fi ltered off, washed with water, and dried. Recrystallization from EtOH/DMF afforded the corresponding thiazole derivative 7a as pale yellow powder in 73% yield. 
6-Bromo-2-(2-cyanomethylthiazol-4-yl)-3-methylthiazolo[3,2-a]benzimidazole (7b)
To a solution of the bromoacetyl derivative 5 (0.39 g, 1 mmol) in absolute ethanol (20 ml), cyanothioacetamide (6b) (0.10 g, 1 mmol) was added. The mixture was refl uxed for 7 h. The solid that formed was fi ltered off, washed with ethanol, and dried. Recrystallization from EtOH/DMF afforded the corresponding thiazole derivative 7b as pale brown fi ne needles in 78% yield. 
General procedure for the reaction of 5 with o-aminothiophenol, o-phenylenediamine and 2-aminopyridine
A mixture of the bromoacetyl derivative 5 (0.39 g, 1.0 mmol) and o-aminothiophenol, o-phenylenediamine or 2-aminopyridine (1.0 mmol) in ethanol (30 ml) was refl uxed for 4 h. The solid that formed was fi ltered off, washed with ethanol, and dried. Recrystallization from DMF/H 2 O afforded the corresponding fused compounds 11a, 11b, and 14, respectively. 
2-(2H
Biological activity assays
Cell culture Several human cell lines were used in testing the anticancer activity including: lymphoblastic leukemia (1301 cells; a generous gift from The Training Center of DakoCytomation, Elly, UK), hepatocellular carcinoma (Hep-G2), colon carcinoma (HCT-116), and Raw murine macrophage (RAW 264.7) (ATCC, VA, USA). Cells were routinely cultured in DMEM (Dulbeco's modifi ed Eagle's medium), except for RAW 264.7 cells, which were grown in RPMI-1640 medium at 37 °C in humidifi ed air containing 5% CO 2 . Media were supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, containing 100 units/ml penicillin G sodium, 100 units/ml streptomycine sulfate, and 250 ng/ml amphotericin B. Monolayer cells were harvested by trypsin/EDTA treatment, except for RAW 264.7 cells, which were collected by gentle scraping. The tested compounds were dissolved in dimethyl sulfoxide (DMSO, 99.9%, HPLC grade) and diluted 1000-fold in the assay solutions. In all cellular experiments, results were compared with DMSO-treated cells. Compound dilutions were tested before assays for endotoxin using the Pyrogent® Ultra gel clot assay, and they were found to be endotoxin-free. All experiments were repeated four times, unless otherwise mentioned, and the data was represented as mean  S.D. Unless other wise mentioned, cell culture material was obtained from Cambrex BioScience (Copenhagen, Denmark), and all chemicals were from Sigma (St. Louis, MO, USA).
Proliferation of immune cells
The effect of the synthesized compounds on the growth of Raw murine macrophages 264.7 and 1301 cells (T-lymphocytes) was estimated by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay (Hansen et al., 1989) . The yellow tetrazolium salt of MTT is reduced by mitochondrial dehydrogenases in metabolically active cells to form insoluble purple formazan crystals, which are solubilized by the addition of a detergent. Cells (5 · 10 4 cells/ well) were incubated with various concentrations of the compounds at 37 °C in a FBS-free medium, before submitted to the MTT assay. The absorbance was measured with an ELISA reader (BioRad, Munich, Germany) at 570 nm. The relative cell viability was determined by the amount of MTT converted to the insoluble formazan salt. The data are expressed as the mean percentage of viable cells as compared to DMSO-treated cells. Treatment of macrophages with 1000 U/ml recombinant macrophage colony-stimulating factor (M-CSF, Pierce, USA) was used as positive control.
Nitrite assay
The accumulation of nitrite, an indicator of NO synthesis, was measured using the Griess reagent (Gerhäuser et al., 2003) . RAW 264.7 cells were grown in phenol red-free RPMI-1640 medium containing 10% FBS. Cells were incubated for 24 h with lipopolysaccharide (LPS) (1 μg/ml) in the presence or absence of the test compounds (12.5 and 25 μg/ml). 50 μl of cell culture supernatant were mixed with 50 μl of Griess reagent and incubated for 10 min. The absorbance was measured spectrophotometrically at 550 nm. A standard curve was plotted using serial concentrations of sodium nitrite. The nitrite content was normalized to the cellular protein content as measured by the bicinchoninic acid assay (Smith et al., 1992) .
The percentage of NO inhibition was calculated by submitting the nitrite contents of the cell supernatants of cultures treated with DMSO (control), LPS, or LPS/test compounds to the following equation: % NO inhibition = (nitrite compound -nitrite control )/(nitrite LPS -nitrite control ) · 100.
Cytotoxicity assay
The effect of the test compounds on the growth of hepatocellular carcinoma (Hep-G2) and colon carcinoma (HCT-116) cells, respectively, was estimated by the MTT assay. The relative cell viability was expressed as the mean percentage of viable cells compared to the respective DMSO-treated cells (control). The half maximal growth inhibitory concentration, IC 50 value, was calculated from the line equation of the dose-response curve of each compound. The results were compared with the cytotoxic activity of paclitaxel, a known anticancer drug, against both cell lines.
Antioxidant assay
The antioxidant capacity of the test compounds was studied through their scavenging activity against 1,1-diphenyl-2-picryl-hydrazyl (DPPH) radicals (Van Amsterdam et al., 1992; Gerhäuser et al., 2003) . The bleaching of DPPH was monitored by the absorbance at 515 nm. The percentage of DPPH bleaching utilized for SC 50 (half maximal scavenging concentration) was calculated as follows: 0% is the absorbance of DPPH and 100% is the absorbance of DPPH with an effi cient scavenger (10 mM ascorbic acid, AA).
Statistical analysis
MTT assay data were analysed using two-factorial analysis of variance (ANOVA), including fi rst-order interactions (two-way ANOVA), followed by the Tukey post hoc test for multiple comparisons. Other test data were analysed using one-way ANOVA followed by the Tukey post hoc test. P < 0.05 indicated statistical signifi cance.
Results and Discussion
Chemistry
The starting material 1-(3-methylthiazolo[3,2-a]benzimidazol-2-yl)ethanone (1) was prepared according to a previously reported method (D'Amico et al., 1964) . The hitherto unreported 1-(6-bromo-3-methyl-1,3-thiazolo[3,2-a]benzimidazol-2-yl)ethanone (2) was prepared by the treatment of 1 with bromine in acetic acid at ambient temperature to afford a single product for which structures 2, 3A, 3B, 3C or 4 seemed possible (Scheme 1).
The 1 H NMR spectrum of the isolated product revealed the singlet signal of the acetyl function at δ 3.08 ppm in addition to the pattern of 1,2,4-substituted benzene, represented as one doublet of doublet signal and two doublets in the aromatic region at δ 7.54 (dd, 1H, J = 8.7, 1.8 Hz, ArH), 7.63 (d, 1H, J = 8.4 Hz, ArH) and 8.23 ppm (d, 1H, J = 1.5 Hz, ArH). These fi ndings ruled out the other possible structure 4, and also excluded the possibilities of bromination at C-5 or C-8 (1,2,3-substituted benzene pattern), which are represented by structures 3B and 3C, respectively, but not enough to exclude the structure 3A, where bromination may take place at C-7. However, the structure 2 was assigned for the reaction product on the basis of its single-crystal X-ray diffraction pattern (Fig. 1) .
We found that, the reaction of 1, using two molar equivalents of bromine in acetic acid at 90 -100 °C, resulted in the corresponding bro- H NMR spectrum revealed the singlet signal of integral to two protons of a methylene group at δ 4.55 ppm and the signals of three aromatic protons at δ 7.54, 7.63 and 8.22 ppm corresponding to C-7, C-8 and C-5, respectively. Its mass spectrum showed a peak corresponding to its molecular ion at m/z 388 [M + ] (Scheme 1). The structure of 5 was further confi rmed by an independent synthesis outlined in Scheme 1. Thus, treatment of 2 with equal molar quantity of bromine in acetic acid at 90 -100 °C resulted in the formation of a product identical to 5.
The reaction of compound 5 with thiourea in refl uxing ethanol afforded the corresponding 1,3-thiazole derivative 7a. The structure of the product was elucidated on the basis of its elemental analysis and spectral data. Its IR spectum revealed the appearance of two absorption bands at 3289 and 3136 cm -1 corresponding to the amino function and showed no carbonyl absorption band in the region 1600 -1750 cm Afterwards, the reaction of 5 with cyanothioacetamide 6a in refl uxing ethanol furnished the cyanomethyl derivative 7b. The IR spectum of 7b showed an absorption band at 2256 cm -1 corresponding to the nitrile function, whereas its 1 H NMR spectrum showed the appearance of a singlet signal of the methylene proton at δ 4.67 ppm and its mass spectrum revealed a peak corresponding to the molecular ion.
When the bromoacetyl derivative 5 was treated with o-aminothiophenol in refl uxing ethanol, it afforded a yellow crystalline product identifi ed as 2-(2H-1,4-benzothiazin-3-yl)-6-bromo-3-methylthiazolo[3,2-a]benzimidazole (11a). Its 1 H NMR spectrum displayed a singlet at δ 3.97 ppm assignable to the two protons of the methylene group in addition to the multiplet signal of seven aromatic protons in the aromatic region. A plausible mechanism for the formation of the 1,4-benzothiazine derivative 11a is depicted in Scheme 2.
Similarly, 5 reacted with o-phenylenediamine to afford the quinoxaline derivative 11b. The structure of the latter product was established from its spectral data, which exclude the other possible structure of the intermediate 10. The IR spectrum of 11b showed the absence of the NH band in the region 3400 -3100 cm -1 , whereas the 1 H NMR spectrum of 11b revealed the characteristic singlet signal due to the proton of C-3 in the quinoxaline moiety at δ 9.4 ppm. A reasonable mechanism for the formation of the product 11b through oxidation of the non-isolable intermediate 10 during the course of the reaction is outlined in Scheme 2.
Furthermore, treatment of 5 with 2-aminopyridine in refl uxing ethanol afforded only one isolable product (as examined by TLC). The structure of the isolated product was identifi ed as 6-bromo-2-imidazo[1,2-a]pyridin-2-yl-3-me thylthiazolo[3,2-a]benzimidazole (14). Its 1 H NMR showed the characteristic singlet of C-3 in the imidazolylpyridine moiety at δ 8.44 ppm, and its mass spectrum revealed a peak corresponding to the molecular ion. The formation of 14 can be explained on the basis of an initial substitution at the ring nitrogen of 2-aminopyridine with α-bromo ketone 5 (Adams and Dix, 1958) to afford the non-isolable intermediate 13. The latter intermediate underwent cyclization into the imidazopyridine derivative 14 via the loss of a water molecule (Scheme 2).
Screening of biological activities
Macrophages are the fi rst line of defense in innate immunity against microbial infection. Phagocytes engulf and kill microorganisms and present antigens for triggering adaptive immune responses (Girotti et al., 2004) . Accordingly, the induction of macrophage proliferation is crucial in the assessment of innate immunity. The treatment with the compounds 2, 5, 7a, 7b, 11a, 11b, and 14 indicated that 7b is a signifi cant stimulator of macrophage growth starting from the lowest tested dose (12.5 μg/ml) with 1.7-fold growth referring to control (P < 0.05) going to the highest tested dose (100 μg/ml) with 2.9-fold growth referring to control (P < 0.01), compared with DMSO-treated cells (Fig. 2) . Surprisingly, 2, 5, and 7a were strong suppressors of macrophage proliferation (Fig. 2) , as indicated by their IC 50 values of 74.06, 61.44, and 89.15 μg/ml, respectively. We further investigated whether the proliferative activity of most of the test compounds is specifi c for macrophages only or towards other immune cells also, so we tested their effect on the growth of T-lymphocytes (lymphoblastic leukemia 1301 cell line). Our fi ndings indicated that 7b, 11b, and 14 were strong dose-dependent in- ducers of the T-lymphocytes growth, but among them, 11b was a dramatic inducer at the tested doses (25 -100 μg/ml, P < 0.001), and the others produced a low slope in the growth curve with increasing doses (Fig. 3A) . Compounds 5, 7a, and 11a were cytotoxic against T-lymphocytes, and their calculated IC 50 values are shown in Fig. 3B , where the most cytotoxic compounds were 7a and 5. From these fi ndings it is obvious that 2, 5, and 7a were strong immunosuppressors (immunotoxic compounds) against both macrophages and T-lymphocytes, and that, among the growth stimulators, compounds 7b, 11b, and 14 were the strongest immunostimulators (immunoproliferative) towards both macrophages and T-lymphocytes. This fast growth within 24 h may be due to a real induction of cell growth through enhancement of DNA synthesis, cell cycle, and/or correlated growth factors such as IL-12 for macrophages and IL-2 for lymphocytes. However, it may be also due to total elevation in the intracellular metabolism, especially mitochondrial dehydrogenases. The effect of the test compounds on the proliferation of macrophages and T-lymphocytes suggested that the skeleton of the bromomethyl thiazolo[3,2-a]-benzimidazole structure was responsible for the immunotoxicity of 2, 5, and 7a against both types of cells, and that only the substitution with the cyanomethyl moiety in the thiazole derivative converted this toxicity into a strong growth stimulatory potency of 7b.
On the other hand, the compounds derived from the immunotoxic bromoacetyl derivative 5 exhibited different effects on the growth of immune cells. Although the benzothiazine derivative 11a possessed a marginal cytotoxicity against 1301 cells, the quinoxaline derivative 11b had a dramatic growth stimulatory effect on both types of immune cells, and the imidazopyridine derivative 14 showed also low growth stimulation of both cell lines.
For exploring the cytotoxic effect of the test compounds on cancer cell lines, Hep-G2 and HCT-116 cells were treated with different doses of the compounds, and then subjected to the MTT assay. The experiment showed that most of the compounds had no effect on the growth of both types of cells, except 2, 5, and 7a, which exhibited a concomitant strong cytotoxic effect on both types of cells as indicated by their IC 50 values in Fig. 3b . The most remarkable cytotoxic compounds against Hep-G2, HCT-116, and 1301 cells were 5, 2, and 7a, respectively. Paclitaxel, the known anticancer agent, was found to have an IC 50 value of 660 ng/ml against Hep-G2 cells and 915 ng/ml against HCT-116 cells.
These fi ndings suggested that the skeleton of the bromomethyl thiazolo[3,2-a]benzimidazole structure was responsible for the cytotoxicity of 2, 5, and 7a against both types of solid tumour cells, and that only the substitution with cyanome- Hep-G2 HCT-116 1301 thyl in the thiazole derivative 7b suppresses this toxicity. On the other hand, it seems that the substitution with benzothiazine in 11a, quinoxaline in 11b, or imidazopyridine in 14 in the cytotoxic bromoacetyl derivative 5 resulted in an effi cient suppression of its cytotoxicity against hepatic and colon carcinoma cells. In the infl ammation process many mediators are involved including cytokine secretion and nitric oxide (NO) (MacMicking et al., 1997) . NO is a highly reactive free radical, and it can form a number of oxidation products (Girotti et al., 2004) . In infl ammatory diseases, NO is produced in large quantities by the action of inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2) (Hu et al., 1992) , leading to infl ammatory consequences and persistent pain.
As a mimic in vitro model of infl ammation, macrophages were stimulated by incubation with the bacterial lipopolysaccharide (LPS), which activates the macrophage functions and the release of infl ammatory mediators including the enhancement of iNOS, the generation of NO, and the secretion of the pro-infl ammatory cytokines. Since most of the cellular generated NO is converted immediately into nitrite, RAW 264.7 cells were stimulated with LPS and the nitrite levels were measured in cell culture supernatants before and after the treatment with safe doses of 12.5 and 25 μg/ml of each compound.
The treatment with 5 led to a dramatic increment in the generation of NO, higher than the LPS-stimulated NO generation (Fig. 4) , while the other compounds inhibited LPS-stimulated NO generation to various degrees, ranging from 14.5% to 88.2% at 25 μg/ml (Fig. 4) . The results also revealed that 14 was the most signifi cant inhibitor of LPS-stimulated NO generation at both tested doses with inhibition ranging from 56.0% to 88.2% (P < 0.05) (Fig. 4) , which suggested a potential anti-infl ammatory activity.
The inhibition of NO may be due to a direct scavenging of NO, inhibition of the iNOS pathway, and/or a modulation of other factors in the NO cascade such as transcriptional factors. Investigation of the radical scavenging activity by the DPPH assay revealed that none of the compounds had radical scavenging activity at the tested concentrations, <100 μg/ml, except 5, 7a, and 7b with calculated SC 50 values of 95.4, 97.0, and 84.2 μg/ml, respectively, i.e. they are weak antioxidants compared with ascorbic acid (SC 50 8.6 μg/ ml). These fi ndings suggested that the NO inhibition was not due to direct scavenging of NO, but rather due to the inhibition of the iNOS cascade.
The effect of the test compounds on NO generation from macrophages suggested that the skeleton of the bromomethyl thiazolo[3,2-a]benzimidazole structure was responsible for the strong inhibition, however, it seems that the substitution with the bromoacetyl moiety in 5 converted this activity into a potential induction of the NO generation from macrophages. This induction may be due to a high induction of the expression on iNOS by this dibromo compound. On the other hand, substitution with imidazopyridine in 14 may lead to the highest inhibition of the iNOS pathway that may lead to its strong inhibition of NO. Fig. 4 . The anti-infl ammatory activity of two doses (12.5 μg/ml as black bars, and 25 μg/ml as white bars) of the synthesized compounds 2, 5, 7a, 7b, 10, 11a, and 14 on NO generation from LPS-stimulated macrophages, in comparison with LPS-treated and untreated (C) macrophages (grey bars). The nitrite concentration, as an index of NO generation, was measured by the Griess assay (mean  S.D., n = 4). Nitrite (μg/mg protein)
